Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
February 10, 2026

Isatuximab / sarclisa for untreated multiple myeloma when a stem cell transplant is unsuitable as of September 2025

MARA Rating Company February 10, 2026

Lorviqua / lorlatinib for aLK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor as of October 2025

MARA Rating Company February 10, 2026

Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia as of December 2025

MARA Rating Company February 10, 2026

Pembrolizumab for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults as of August 2025

MARA Rating Company February 10, 2026

Kisqali / ribociclib for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence as of August 2025

MARA Rating Company February 10, 2026

Ruxolitinib / opzelura for treating non-segmental vitiligo in people 12 years and over as of August 2025

MARA Rating Company February 10, 2026

Sparsentan for treating primary IgA nephropathy as of October 2025

MARA Rating Company February 10, 2026

Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments as of December 2025

MARA Rating Company February 10, 2026

Kinpeygo / budesonide for treating primary IgA nephropathy as of October 2025

MARA Rating Company February 10, 2026

Tarlatamab / imdylltra for extensive-stage small-cell lung cancer after 2 or more treatments as of August 2025

MARA Rating Company February 10, 2026